Winston Pharmaceutcl (WPHM) 0.0100 $WPHM
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Rheumatoid Arthritis Pain - Pipeline Review, H2 2013
M2 - Mon Nov 18, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/q9fmtn/rheumatoid) has announced the addition of the "Rheumatoid Arthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis Pain. - A review of the Rheumatoid Arthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Array BioPharma Inc. Futura Medical plc. Winston Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q9fmtn/rheumatoid About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Inflammatory Pain - Pipeline Review, H2 2013
M2 - Fri Aug 02, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfg3xp/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Inflammatory Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Pain. Inflammatory Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Inflammatory Pain. - A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Inflammatory Pain Therapeutics Development - Boehringer Ingelheim GmbH - Shionogi & Co., Ltd. - AstraZeneca PLC - MedImmune LLC - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Evotec Aktiengesellschaft - Anavex Life Sciences Corp. - CombinatoRx, Incorporated - Array BioPharma Inc. - Neurim Pharmaceuticals (1991) Ltd. - Pluristem Therapeutics Inc. - Palau Pharma S.A - Probiodrug AG - AngioChem Inc. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Winston Pharmaceuticals, Inc. - NeuroTherapeutics Pharma Inc. - CLL Pharma - Spinifex Pharmaceuticals Pty Limited - MAKScientific, LLC - RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/mf...atory_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Postherpetic Neuralgia - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f66v5t/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Postherpetic Neuralgia. - A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Postherpetic Neuralgia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Postherpetic Neuralgia Overview Therapeutics Development An Overview of Pipeline Products for Postherpetic Neuralgia Companies Involved in Postherpetic Neuralgia Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Allergan, Inc - Amgen Inc - Arcion Therapeutics - Bial - Portela & Ca, S.A - Bristol-Myers Squibb Company - Celtic Pharmaceutical Holdings L.P - DURECT Corporation - Daewoong Pharmaceutical Co - EpiCept Corporation - Kyowa Hakko Kirin Co - NeurogesX, Inc - SantoSolve AS - Spinifex Pharmaceuticals Pty Limited - TheraQuest Biosciences, LLC - Valeant Pharmaceuticals International - Winston Pharmaceuticals - Xenon Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/research/f6...stherpetic
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Rheumatoid Arthritis Pain - Pipeline Review, H2 2013
M2 - Mon Nov 18, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/q9fmtn/rheumatoid) has announced the addition of the "Rheumatoid Arthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis Pain. - A review of the Rheumatoid Arthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Array BioPharma Inc. Futura Medical plc. Winston Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q9fmtn/rheumatoid About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Inflammatory Pain - Pipeline Review, H2 2013
M2 - Fri Aug 02, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfg3xp/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Inflammatory Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Pain. Inflammatory Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Inflammatory Pain. - A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Inflammatory Pain Therapeutics Development - Boehringer Ingelheim GmbH - Shionogi & Co., Ltd. - AstraZeneca PLC - MedImmune LLC - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Evotec Aktiengesellschaft - Anavex Life Sciences Corp. - CombinatoRx, Incorporated - Array BioPharma Inc. - Neurim Pharmaceuticals (1991) Ltd. - Pluristem Therapeutics Inc. - Palau Pharma S.A - Probiodrug AG - AngioChem Inc. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Winston Pharmaceuticals, Inc. - NeuroTherapeutics Pharma Inc. - CLL Pharma - Spinifex Pharmaceuticals Pty Limited - MAKScientific, LLC - RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/mf...atory_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Postherpetic Neuralgia - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f66v5t/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Postherpetic Neuralgia. - A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Postherpetic Neuralgia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Postherpetic Neuralgia Overview Therapeutics Development An Overview of Pipeline Products for Postherpetic Neuralgia Companies Involved in Postherpetic Neuralgia Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Allergan, Inc - Amgen Inc - Arcion Therapeutics - Bial - Portela & Ca, S.A - Bristol-Myers Squibb Company - Celtic Pharmaceutical Holdings L.P - DURECT Corporation - Daewoong Pharmaceutical Co - EpiCept Corporation - Kyowa Hakko Kirin Co - NeurogesX, Inc - SantoSolve AS - Spinifex Pharmaceuticals Pty Limited - TheraQuest Biosciences, LLC - Valeant Pharmaceuticals International - Winston Pharmaceuticals - Xenon Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/research/f6...stherpetic
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
